Cargando…

Targeted Therapies Development in the Treatment of Advanced Nonsmall Cell Lung Cancer

Detalles Bibliográficos
Autores principales:	Gridelli, Cesare, Felip, Enriqueta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2011
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3246899/ https://www.ncbi.nlm.nih.gov/pubmed/22219656 http://dx.doi.org/10.1155/2011/415641

Ejemplares similares

Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)
por: Felip, Enriqueta, et al.
Publicado: (2008)

Gemcitabine for the treatment of advanced nonsmall cell lung cancer
por: Toschi, Luca, et al.
Publicado: (2009)

Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer
por: Dienstmann, Rodrigo, et al.
Publicado: (2011)

New developments in locally advanced nonsmall cell lung cancer
por: Huber, Rudolf M., et al.
Publicado: (2021)

Critical points in the management of EGFR-mutated non-small cell lung cancer
por: Casaluce, Francesca, et al.
Publicado: (2022)

Radio(chemo)therapy in locally advanced nonsmall cell lung cancer
por: Glatzer, Markus, et al.
Publicado: (2016)

Effect of targeted therapy and immunotherapy on advanced nonsmall‐cell lung cancer outcomes in the real world
por: Shokoohi, Aria, et al.
Publicado: (2021)

The Role of Immunotherapy in the First-Line Treatment of Elderly Advanced Non-Small Cell Lung Cancer
por: Spagnuolo, Alessia, et al.
Publicado: (2023)

Modern therapies of nonsmall cell lung cancer
por: Jachowski, Andrzej, et al.
Publicado: (2023)

Clinicopathological features and outcomes in advanced nonsmall cell lung cancer with tailored therapy
por: Bala, Stalin, et al.
Publicado: (2016)

Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives
por: Cheng, Xinghua, et al.
Publicado: (2014)

The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target—a narrative review
por: Spagnuolo, Alessia, et al.
Publicado: (2022)

The New Immunotherapy Combinations in the Treatment of Advanced Non-Small Cell Lung Cancer: Reality and Perspectives
por: Rocco, Danilo, et al.
Publicado: (2020)

The Possibility of Traditional Chinese Medicine as Maintenance Therapy for Advanced Nonsmall Cell Lung Cancer
por: Xu, Weiru, et al.
Publicado: (2014)

Second-line avelumab in platinum-treated non-small cell lung cancer patients: comment on the JAVELIN Lung 200 clinical trial
por: Rocco, Danilo, et al.
Publicado: (2019)

Bronchoscopic treatment of inoperable nonsmall cell lung cancer
por: Kniese, Christopher M., et al.
Publicado: (2020)

Therapeutic options targeting angiogenesis in nonsmall cell lung cancer
por: Crinò, Lucio, et al.
Publicado: (2014)

Molecular Imaging in Therapeutic Efficacy Assessment of Targeted Therapy for Nonsmall Cell Lung Cancer
por: Hu, Yanni, et al.
Publicado: (2012)

Advances in the Treatment of Rare Epidermal Growth Factor Receptor Mutations in Advanced Nonsmall-Cell Lung Cancer
por: Yu, Limeng, et al.
Publicado: (2023)

Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes
por: Rocco, Danilo, et al.
Publicado: (2023)

Evaluation of Three Small Molecular Drugs for Targeted Therapy to Treat Nonsmall Cell Lung Cancer
por: Ni, Jun, et al.
Publicado: (2016)

Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity
por: Cobo, Manuel, et al.
Publicado: (2017)

Personalised medicine for nonsmall cell lung cancer
por: Mascaux, Céline, et al.
Publicado: (2017)

Tyrosine kinase inhibitors as induction therapy in nonsmall-cell lung cancer
por: Gong, Juejun, et al.
Publicado: (2021)

The adjuvant regimen for resected EGFR mutated patients: the “same-for-all-therapy” or not?
por: Gridelli, Cesare, et al.
Publicado: (2020)

Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer
por: Costantini, Adrien, et al.
Publicado: (2018)

Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)
por: Kobayashi, Kunihiko, et al.
Publicado: (2013)

Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2020)

Spontaneous regression of locally advanced nonsmall cell lung cancer: A case report
por: Ooi, Kiat Huat, et al.
Publicado: (2018)

Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2017)

TP53 Mutations in Nonsmall Cell Lung Cancer
por: Mogi, Akira, et al.
Publicado: (2011)

Signatures of Drug Sensitivity in Nonsmall Cell Lung Cancer
por: Gong, Hua C., et al.
Publicado: (2011)

The Role of Proteasome Inhibition in Nonsmall Cell Lung Cancer
por: Escobar, Mauricio, et al.
Publicado: (2011)

Thyroid Metastasis from Nonsmall Cell Lung Cancer
por: Namad, Tariq, et al.
Publicado: (2013)

An IMRT/VMAT Technique for Nonsmall Cell Lung Cancer
por: Zhao, Nan, et al.
Publicado: (2015)

Narrative review of lung cancer treatment at the time of COVID-19 pandemia: pitfall and issues
por: Casaluce, Francesca, et al.
Publicado: (2021)

Assessment on the Efficacy and Safety of Aidi Injection Combined with Vinorelbine and Cisplatin for Treatment of Advanced Nonsmall Cell Lung Cancer
por: Zhao, Hua-Ye, et al.
Publicado: (2016)

Novel peptide–dendrimer conjugates as drug carriers for targeting nonsmall cell lung cancer
por: Liu, Jianfeng, et al.
Publicado: (2011)

Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer
por: Haslam, Sonya, et al.
Publicado: (2007)

Tailoring treatment of nonsmall cell lung cancer by tissue type: role of pemetrexed
por: Powell, Steven F, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_jl04lpr66vvfdnbokccga5199j